Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2003 Feb 11;52(3):145–154. doi: 10.1007/s00262-002-0340-0

Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside

Saroj Basak 1, Brigitte Birebent 1, Enkhtsetseg Purev 1, Rajasekharan Somasundaram 1, Haruhiko Maruyama 1, Jan Zaloudik 1, Rolf Swoboda 1, Wolfgang Strittmatter 2, Weiping Li 1, Albrecht Luckenbach 2, Hong Song 1, Jian Li 1, Katrin Sproesser 1, Dupont Guerry 3, Sridar Nair 1, Koichi Furukawa 4, Dorothee Herlyn 1
PMCID: PMC11033031  PMID: 12649743

Abstract.

Gangliosides are potentially useful targets for tumor destruction by antibodies. However, the role of gangliosides in T cell-mediated immunity to tumors is unclear. We produced three murine monoclonal anti-idiotypic antibodies (Ab2) against a monoclonal antibody (Ab1) that binds strongly to melanoma-associated GD2 ganglioside and weakly to GD3 ganglioside. All three Ab2 induced anti-anti-idiotypic antibodies (Ab3) with Ab1-like binding specificity to tumor cells and antigen in rabbits. The Ab3 specifically bound to GD2+ tumor cells and isolated GD2, and shared idiotopes with the Ab1. Two of the three Ab2 induced GD2-specific delayed-type hypersensitivity responses in BALB/c and C57BL/6 mice, but not in C57BL/6/CD4–/– mice. Peripheral blood mononuclear cells (PBMC) from a melanoma patient proliferated specifically in response to in vitro stimulation with Ab2. Proliferation was accompanied by Th1-type cytokine production. Our studies demonstrate the induction of ganglioside-specific T cell-dependent immunity by Ab2 in mice. These T cells showed specific reactivity to ganglioside expressed by tumor cells.

Keywords: Anti-idiotypic antibody Cellular immunity GD2 ganglioside Melanoma

Footnotes

Electronic Publication


Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES